These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10973109)

  • 1. [Quantitative electroencephalography in obsessive-compulsive disorder: preliminary results].
    Fontenelle L; Piedade RA; Marques C; de Menezes GB; Versiani M
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):677-82. PubMed ID: 10973109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of treatment resistance in obsessive compulsive disorder patients based on EEG complexity as a biomarker.
    Altuğlu TB; Metin B; Tülay EE; Tan O; Sayar GH; Taş C; Arikan K; Tarhan N
    Clin Neurophysiol; 2020 Mar; 131(3):716-724. PubMed ID: 32000072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered frontal EEG asymmetry in obsessive-compulsive disorder.
    Ischebeck M; Endrass T; Simon D; Kathmann N
    Psychophysiology; 2014 Jul; 51(7):596-601. PubMed ID: 24673721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative electroencephalography in OCD patients treated with paroxetine.
    Hansen ES; Prichep LS; Bolwig TG; John ER
    Clin Electroencephalogr; 2003 Apr; 34(2):70-4. PubMed ID: 12784904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Tükel R; Bozkurt O; Polat A; Genç A; Atli H
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):404-9. PubMed ID: 16884439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
    Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M
    CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lee GE; Yun JM; Yang SB; Kang Y; Kang HW; Choi KH; Kim J; Kwon OS; Park JE; Kim JH
    Evid Based Complement Alternat Med; 2017; 2017():7107136. PubMed ID: 28484506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
    Stein DJ; Montgomery SA; Kasper S; Tanghoj P
    Int Clin Psychopharmacol; 2001 Nov; 16(6):357-61. PubMed ID: 11712625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making.
    da Conceição Costa DL; Shavitt RG; Castro Cesar RC; Joaquim MA; Borcato S; Valério C; Miguel EC; Diniz JB
    J Psychiatr Res; 2013 Nov; 47(11):1700-7. PubMed ID: 23948637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
    Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
    J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
    Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results.
    Külz AK; Meinzer S; Kopasz M; Voderholzer U
    Neuropsychobiology; 2007; 56(2-3):127-31. PubMed ID: 18259085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications.
    Masi G; Perugi G; Millepiedi S; Toni C; Mucci M; Pfanner C; Berloffa S; Pari C; Akiskal HS
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):475-86. PubMed ID: 17822342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.